Under construction – not a live service
Sign in
Taking people in FranceNo phase

Combined Gene Sequencing to Find Genetic Causes of Parkinsonism

Tests combined genome and RNA sequencing to find genetic causes in adults with parkinsonism.

Plain-language title generated from the registry record
Registry title: Combined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism

Key facts

Where
Strasbourg, FranceSee the site

Where in France

  • Hopitaux Universitaires de StrasbourgStrasbourg, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital, Strasbourg, France
Trial code
NCT06576713
Record updated
21 August 2026
Original description
Despite the increasing availability and advances in the analysis of high-throughput DNA sequencing, the majority of patients with early-onset or familial parkinsonism remain without a molecular diagnosis.Read full original descriptionShow less

Identification of the Missing Genetic Causes of Parkinsonian Syndromes: a Combined Approach by Genome and RNA Sequencing

Despite the increasing availability and advances in the analysis of high-throughput DNA sequencing, the majority of patients with early-onset or familial parkinsonism remain without a molecular diagnosis.

Studying the genetic forms of parkinsonian syndromes presents numerous clinical, scientific and therapeutic interests. In clinical practice, identifying the genetic cause in a patient allow to provide genetic counseling and estimate the risk of recurrence in their relatives. Establishing correlations between the genotype and phenotype of patients with genetically determined parkinsonism, allow to better anticipate the evolution of the disease, or even to highlight biomarkers during the presymptomatic phases. Finally, the proteins encoded by the genes implicated in familial parkinsonism represent potential therapeutic targets likely to be modulated by neuroprotective pharmacological agents, even in sporadic Parkinson's disease.

In this work,investigators aimed at elucidating the missing genetic causes of parkinsonism through the application of combined RNA and whole genome sequencing.

Inclusion: Extrapyramidal syndrome beginning before or at the age of 40 or associated with a family history:; Dopaminergic denervation proven by ioflupane brain scintigraphy (DaTscan®); DNAs from both asymptomatic parents available in biobank; Subject affiliated to a social protection health insurance scheme or beneficiary or beneficiary; Subject able to understand the objectives and risks related to the research and to give dated and signed informed consent.

Exclusion: Molecular cause of parkinsonism previously identified; Absence of prior genetic exploration by high-throughput DNA sequencing; Patient with Parkinson's syndrome associated with a specific diagnosis (genetic or non-genetic pathology: exposure to neuroleptics, toxic origin); Patient with late-onset sporadic parkinsonian syndrome (> 40 years) without family history; - Contraindication for performing a superficial skin biopsy provided for by the protocol; Impossibility of providing the subject with informed information; Subject under judicial protection; Subject under guardianship or curatorship.

ClinicalTrials.gov NCT06576713